Announcements Trials

Browse Landscape

Phase

Phase 3 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 9 Neoplasms 2 Fallopian Tube Neoplasms 2 Breast Neoplasms 2 Triple Negative Breast Neoplasms 1 Recurrence 1 Prostatic Neoplasms, Castration-Resistant 1 Metastatic Castration-sensitive Prostate Cancer 1 Metastatic Castration-resistant Prostate Cancer (mCRPC) 1 Glioblastoma 1 Carcinoma, Ovarian Epithelial 1 Carcinoma, Non-Small-Cell Lung 1 Brain Neoplasms 1 Biliary Tract Neoplasms 1

Interventions

Carboplatin 190 Cisplatin 156 Pemetrexed 151 Paclitaxel 127 Docetaxel 109 pembrolizumab 87 Gemcitabine 73 Erlotinib Hydrochloride 44 Radiotherapy 39 Vinorelbine 35 Gefitinib 34 durvalumab 31 Bevacizumab 28 Nivolumab 26 Drug Therapy 23 atezolizumab 22 osimertinib 19 130-nm albumin-bound paclitaxel 19 tislelizumab 16 Crizotinib 16 Radiosurgery 15 Etoposide 14 Surgical Procedures, Operative 11 Afatinib 11 Ipilimumab 10 icotinib 9 aumolertinib 9 Albumin-Bound Paclitaxel 9 Specimen Handling 8 Observation 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Carcinoma, Non-Small-Cell Lung × niraparib × Clear all

NCT04475939 2026-05-01

ZEAL-1L

GlaxoSmithKline

Phase 3 Completed

666 enrolled 21 charts

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡